R&G PharmaStudies Co., Ltd. (SHE:301333)
China flag China · Delayed Price · Currency is CNY
50.70
+3.38 (7.14%)
At close: Aug 4, 2026

R&G PharmaStudies Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
133.65136.9140.22162.53113.4599.24
Depreciation & Amortization
20.3320.3336.3134.5719.0336.05
Other Amortization
17.0617.061.42.1917.41.59
Loss (Gain) From Sale of Assets
0.010.010.070.020.020.02
Asset Writedown & Restructuring Costs
---0--
Loss (Gain) From Sale of Investments
-21.1-21.1-24.95-27.44-9.14-2.6
Provision & Write-off of Bad Debts
5.195.193.364.863.577.54
Other Operating Activities
4.658.284.960.23-3.563.29
Change in Accounts Receivable
-49.72-49.72-54.95-20.08-42.52-58.34
Change in Inventory
6.226.22-4.231.75-9.74-14.6
Change in Accounts Payable
6.886.8852.1921.6642.5543.5
Change in Other Net Operating Assets
-13.98-13.98-0.0213.270.220.36
Operating Cash Flow
107.32114.2154.76192.56130.47114.57
Operating Cash Flow Growth
-10.77%-26.21%-19.63%47.60%13.87%159.80%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-18.79-19.28-19.98-19.88-20.83-38.28
Sale of Property, Plant & Equipment
0.010.010.010.020.150.09
Cash Acquisitions
-24-24-21.31---
Investment in Securities
330.6741.5-26-710--
Other Investing Activities
17.3620.8722.9525.059.142.6
Investing Cash Flow
305.2419.11-44.33-704.8-11.54-35.59

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
--54.79---
Total Debt Issued
--54.79---
Long-Term Debt Repaid
--69.01-14.36-12.74-11.5-9.94
Net Debt Issued (Repaid)
-18.87-69.0140.43-12.74-11.5-9.94
Issuance of Common Stock
1.011.0115.18-1,114-
Repurchase of Common Stock
---56.09---
Common Dividends Paid
-11.78-11.78-28.38-5.82--
Other Financing Activities
-2.4810.75-19.87--66.99-
Financing Cash Flow
-32.12-69.03-48.74-18.561,036-9.94

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-6.38-3.721.761.15.44-1.27
Net Cash Flow
374.0660.5663.44-529.691,16067.77

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
88.5294.93134.78172.68109.6476.29
Free Cash Flow Growth
-11.07%-29.57%-21.95%57.50%43.71%309.66%
Free Cash Flow Margin
9.88%11.15%18.12%23.94%17.20%12.54%
Free Cash Flow Per Share
0.930.991.411.801.331.06
Levered Free Cash Flow
54.6764.94116.07133.1980.644.54
Unlevered Free Cash Flow
56.3266.73118.22133.5681.0244.9

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
56.9158.3452.1555.140.945.16
Change in Working Capital
-52.47-52.47-6.6215.6-10.3-30.55